Skip to Content

Newsroom

Study Shows Weekly Taxol® Significantly Improves Remission Rates in Early-Stage Breast Cancer Patients

Study Shows Weekly Taxol® Significantly Improves Remission Rates in Early-Stage Breast Cancer Patients
M. D. Anderson News Release 05/10/01

A new study demonstrates that weekly Taxol® (paclitaxel) followed by a standard chemotherapy regimen before surgery significantly increases remission rates for patients with early-stage breast cancer.

According to the study, node-negative breast cancer patients receiving Taxol once a week prior to a standard chemotherapy regimen achieved 63 percent higher remission rates, as confirmed by surgery, compared to the standard once per three-week schedule. Node-positive patients achieved a 40 percent increase in remission rates with weekly Taxol.

"This trial is the first evidence that weekly infusions of Taxol are better than the three-week standard," said investigator Dr. Gabriel Hortobagyi, chairman of the Department of Breast Medical Oncology at M. D. Anderson Cancer Center. "Since higher pathological complete remission rates equate with increased survival, this is good news for early-stage breast cancer patients."

5/10/01


© 2014 The University of Texas MD Anderson Cancer Center